Agreed, but I believe USRM is in the power of the bargaining position and has leverage over Northstar. Why else would Northstar be squabbling over the additional 5% in international sales. As I understand it, that is the difference in opinions. If USRM would grant them 10% of international sales, then the final settlement would have already been entered. The important point here is to grasp that obviously Northstar has acceded to the following points:
1) MYOCELL works and when the Pivotal Trial results are released, that will be proven.
2) Predicated upon point 1, the international sales will be extremely lucrative and Northstar wants a larger premium on those sales.
3) Predicated upon point #2, a buyout of USRM outright, would put Northstar in a better position with the acquiring company to negotiate a higher premium to buy them out of the royalty deal.
This is basic economics and business negotiations. Northstar knows what USRM has, as does USRM, and neither wants to sell cheap.
It does not take a rocket scientist to draw a conclusion upon reading the disclosed court documents and seeing that USRM has had numerous buyout offers but has to settle with Northstar before signing on the proverbial, dotted line. We do not want USRM to sell n the cheap, I would think they would ask us share holders to not do the same. Hold your shares.
Market Data 
Markets 
AI
